Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 26 citing articles:

Adalimumab‐Induced Cutaneous Lupus Erythematosus: Cases Presenting With Malar Rash and Panniculitis
Parvin Mansouri, Farahnaz Bidari‐Zerehpoosh, Nikoo Mozafari
Clinical Case Reports (2025) Vol. 13, Iss. 1
Open Access | Times Cited: 1
The Intriguing Links between Psoriasis and Bullous Pemphigoid
Carlo Alberto Maronese, Nicoletta Cassano, Giovanni Genovese, et al.
Journal of Clinical Medicine (2022) Vol. 12, Iss. 1, pp. 328-328
Open Access | Times Cited: 23
Paradoxical Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor-Induced Psoriasis: A Systematic Review of Pathogenesis, Clinical Presentation, and Treatment
Aditi Chokshi, Michelle Demory Beckler, Anita Laloo, et al.
Cureus (2023)
Open Access | Times Cited: 12
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
Maria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 10, pp. 3545-3545
Open Access | Times Cited: 11
Targeting nail psoriasis: IL-17A inhibitors demonstrate site-specific superiority over IL-23 inhibitor in a 24-week dermoscopy-guided real-world cohort
Yan Xia, Minglan Shi, Bin Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Janus kinase of all trades? Treatment of ixekizumab and dupilumab-related paradoxical reactions with upadacitinib
Ping-Yi Tsai, Yu Yu
Dermatologica Sinica (2025)
Open Access
IL-17 family cytokines in inflammatory or autoimmune skin diseases
Baida Kong, Yuping Lai
Advances in immunology (2024), pp. 21-49
Closed Access | Times Cited: 3
Rheumatic adverse events associated with biologic therapy for chronic rhinosinusitis: A systematic review and meta‐analysis
Jenny B. Xiao, Helen Hsiao, Carlos Khalil, et al.
International Forum of Allergy & Rhinology (2024) Vol. 14, Iss. 10, pp. 1618-1633
Open Access | Times Cited: 3
Paradoxical reactions to biologicals for psoriasis
Elisa Camela, Luca Potestio, Gabriella Fabbrocini, et al.
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 12, pp. 1435-1437
Closed Access | Times Cited: 12
A Case of Paradoxical Reactions to Biologic Therapy for Psoriasis
Qianqian Zhou, Shengru Zhou, Huizi Xiong, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 1493-1497
Open Access | Times Cited: 5
Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17/IL-23 Axis in Patients with Hidradenitis Suppurativa
Aikaterini Tsiogka, Aikaterini I. Liakou, Efthimia Agiasofitou, et al.
Dermatology (2023) Vol. 239, Iss. 6, pp. 937-941
Closed Access | Times Cited: 4
Secukinumab-Induced Alopecia Areata Successfully Treated with Tofacitinib in a Patient with Palmoplantar Pustulosis
Chen Zhang, Tianlun Kang, Tangliang Qian, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 2879-2883
Open Access | Times Cited: 4
Local injection of micro‐dose guselkumab for palmoplantar pustulosis after partial failure of systemic ixekizumab treatment
ChaoJing Zhou, DanDan Chen, ZiYue Diao, et al.
Australasian Journal of Dermatology (2024) Vol. 65, Iss. 3
Closed Access | Times Cited: 1
Investigating the Impact of Secukinumab Bulk and Liposome Forms on Lymphocytes from Psoriasis Patients, as Compared to Healthy Controls, to Determine the Improvement in Bioavailability of Secukinumab Nanoliposomes
Gazala Layas, Mohammad Isreb, Nader Ghaderi, et al.
(2024)
Open Access | Times Cited: 1
Authors’ Reply to Wang et al., “Comment on ‘Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial’”
Yukari Okubo, Satomi Kobayashi, Masamoto Murakami, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 6, pp. 1025-1027
Open Access | Times Cited: 1
Pathomechanism of Adverse Reactions to Biological Treatment of Inflammatory Skin Conditions
Lichen Li, Dean J. Naisbitt, Yonghu Sun, et al.
Clinical & Experimental Allergy (2024) Vol. 54, Iss. 12, pp. 973-983
Open Access | Times Cited: 1
Hidradenitis suppurativa pathogenesis: Extrinsic factors
Valdemar Wendelboe Nielsen, Simon Francis Thomsen, Haley B. Naik
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 6, pp. S17-S21
Closed Access | Times Cited: 1
Immune Portrayal of a New Therapy Targeting Microbiota in an Animal Model of Psoriasis
Mihaela Surcel, Carolina Constantin, Adriana Munteanu, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 11, pp. 1556-1556
Open Access | Times Cited: 2
Adalimumab-induced paradoxical pustular psoriasis and alopecia successfully treated with ixekizumab in a patient affected by hidradenitis suppurativa
Carlo Alberto Vignoli, Luigi Gargiulo, Federica Sanna, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 1
Deep analysis of skin molecular heterogeneities and their significance on the precise treatment of patients with psoriasis
Sheng‐Xiao Zhang, M. J. Chang, Leilei Zheng, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Paradoxical Psoriasis in Patients Receiving Therapy with Tumor Necrosis Factor Inhibitors: Potential Pathogenic Mechanisms and the Role of Genetic Factors
D Costin, Alexandra Burlui, Anca Cardoneanu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7018-7018
Open Access
Successful Treatment of Adalimumab-Induced Paradoxical Skin Reactions in Pustulotic Arthro-Osteitis With Guselkumab
Kazuki Yatsuzuka, Takuya Matsumoto, Teruki Kidani, et al.
Cureus (2024)
Open Access
Secukinumab-Aggravated Disseminated Discoid Lupus Erythematosus Misdiagnosed as Psoriasis
Binrong Ye, Dongmei Liu, Chen Tu, et al.
Cureus (2024)
Open Access
Pityriasis Versicolor in Dupilumab-Treated Atopic Dermatitis Patients: A Possible Underestimated Side Effect
Lucía García Sirvent, A.A. González Ruiz, Pedro Gil Pallares, et al.
Dermatitis (2023) Vol. 35, Iss. 3, pp. 307-308
Closed Access
Assessment of Serum Interleukin-23 in Acne Vulgaris Patients and Its Correlation with Disease Severity
Mohammed Sultan, Magdy Abdelmageed Elsohafy, Manal El-Dsouky, et al.
The Egyptian Journal of Hospital Medicine (2023) Vol. 92, Iss. 1, pp. 6269-6275
Open Access
Page 1 - Next Page

Scroll to top